Pharmacological inhibition of caspase 8 has been shown to reduce tumor growth by reducing the release of pro-inflammatory cytokines (IL-6, TNF-α, IL-18, IL-1α, IL-33), decreased recruitment of innate suppressor cells, and higher cellular FLICE-like inhibitors protein (c-FLIP) expression, which determines the progression of lung cancer [14]. This evidence concerns the gene CASP8 and lung carcinoma.